BrainsWay (NASDAQ:BWAY) Issues Earnings Results

BrainsWay (NASDAQ:BWAY) issued its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03, Zacks reports. BrainsWay had a return on equity of 3.56% and a net margin of 3.88%. The company had revenue of $10.50 million for the quarter, compared to analysts’ expectations of $10.07 million. During the same period last year, the firm earned ($0.01) EPS. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Stock Up 5.4 %

Shares of BWAY traded up $0.49 during mid-day trading on Thursday, hitting $9.53. 109,687 shares of the company’s stock were exchanged, compared to its average volume of 95,952. The stock has a market cap of $158.94 million, a price-to-earnings ratio of 94.20 and a beta of 1.25. The firm has a fifty day moving average of $9.19 and a two-hundred day moving average of $7.45. BrainsWay has a twelve month low of $4.16 and a twelve month high of $10.98.

Wall Street Analysts Forecast Growth

BWAY has been the topic of a number of recent research reports. Northland Securities lifted their target price on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a report on Thursday, October 3rd. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a research report on Monday, October 21st.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.